Temoporfin (m-THPC), a reduced porphyrin, is a potent second-generation photosensitizer. Temoporfin can be used in the research of photodynamic therapy (PDT) for head and neck cancers . In Vitro A detailed confocal fluorescence microscopy study of a human adenocarcinoma shows weak localization of Temoporfin in lysosomes and mitochondria. Instead, it is found to be localized in the endoplasmic reticulum (ER) and the Golgi apparatus. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Temoporfin in liver tissue decreases rapidly in time after initial high levels at 4 h after administration (0.1-0.3 mg/kg). In tumour tissue no decrease in photosensitizer levels occurred, with Temoporfin remaining high up to 48 h after administration. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid